IoNxt Solutions Inc. has announced the expansion and protection of its proprietary drug delivery platform focusing on neurological autoimmune disorders. The company has begun the examination process for its U.S. patent application for BNT23001, a novel sublingual thin-film cladribine formulation for multiple sclerosis (MS), under the United States Patent and Trademark Office's (USPTO)... https://www.coherentmarketinsights.com/news/bionxt-accelerates-us-patent-for-ms-drug-expands-autoimmune-neurology-pipeline-1361